VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live better, today announced that it closed the previously announced credit agreement refinancing. In connection with the closing, Bausch + Lomb has entered into a fourth amendment (the … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Protein Engineering for Pharmaceutical Biotechnology Training Course (Jan 21st – Jan 22nd, 2026)” training has been added to ResearchAndMarkets.com’s offering. Enhance your knowledge in protein engineering to understand how to advance therapeutic development and industrial applications. Protein-based therapeutics have significantly advanced and created new paradigms in disease treatment. Half of the top ten … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Successful Medical Writing – from Protocol to CTD Training Course (Mar 23rd – Mar 24th, 2026)” training has been added to ResearchAndMarkets.com’s offering. Success in the pharmaceutical industry depends on the speed and efficiency of new drug approvals. This process largely relies on the quality of documentation submitted to the regulatory authorities, and … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Cell Therapy Processing: Global Markets and Technologies” report has been added to ResearchAndMarkets.com’s offering. The global market for cell therapy processing is estimated to grow from $2.7 billion in 2025 to reach $7.1 billion by 2030, at a compound annual growth rate (CAGR) 21.4% from 2025 to 2030. According to the American Society … [Read more…]
PRINCETON, N.J.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced that the company will present at J.P. Morgan’s 44th Annual Healthcare Conference on Monday, January 12, 2026. The company’s presentation and participation in a fireside chat will begin at 7:30 a.m. PST/10:30 a.m. ET. The event will be webcast simultaneously at http://investor.bms.com, with materials related to … [Read more…]
RAPPERSWIL, Switzerland–(BUSINESS WIRE)–Dr. Christian Loss, Chief Executive Officer (CEO) of Neovii Pharmaceuticals AG, will take a well-deserved retirement after his distinguished career at Neovii. As of January, he is succeeded by Frédéric Prince PhD, who most recently served as Head of Strategy and Chief of Staff ad interim to the Head of Oncology in Roche’s … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “AtriCure Inc (ATRC) – Product Pipeline Analysis, 2025 Update” company profile has been added to ResearchAndMarkets.com’s offering. This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands. AtriCure Inc (AtriCure) is a … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Cell & Gene Therapies in Respiratory Disorders: Therapeutic Analysis” report has been added to ResearchAndMarkets.com’s offering. The cell and gene therapies (CGTs) landscape for respiratory diseases is currently in the early stages of development, with no marketed CGTs to date. Reasons to Buy Develop and design your in-licensing and out-licensing strategies through a … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Diabetic Macular Edema (DME): Epidemiology Forecast to 2034” report has been added to ResearchAndMarkets.com’s offering. In the 7MM, the diagnosed prevalent cases of DME in diabetes are expected to increase from 2,888,125 cases in 2024 to 3,463,149 cases in 2034, at an annual growth rate (AGR) of 1.99%. In 2034, the US will … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Sysmex Corp (6869) – Product Pipeline Analysis, 2025 Update” company profile has been added to ResearchAndMarkets.com’s offering. This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands. Sysmex Corp (Sysmex) is a … [Read more…]
